miércoles, 11 de junio de 2014

CDER SBIA Update: FDA issues final rule on postmarketing safety report in electronic format

FDA Transparency Blog

FDA/CDER's Small Business and Industry Assistance (CDER SBIA)

FDA issues final rule on postmarketing safety report in electronic format

FDA issued a final rule on June 10, 2014, that requires industry to submit postmarketing safety reports in an electronic format. The final rule and accompanying draft guidance, Providing Submissions in Electronic Format—Postmarketing Safety Reports, applies to virtually all postmarketing safety reports for human drug and biologic products, which includes individual case safety reports (ICSRs) and periodic safety reports.
These new requirements are expected to improve FDA’s ability to process and archive postmarketing safety reports in a timely manner, and make postmarketing reports more readily available for analysis.
These requirements will save FDA about $0.8 million annually, primarily in the cost of processing paper.
Unlike paper submissions, electronically submitted reports are available for analysis as soon as they have been processed by FDA. For example, data from ICSRs submitted electronically are generally available to reviewers within two days of receipt rather than 10-60 days, depending on the type of report.
The final rule is also an important step in harmonizing FDA’s postmarketing safety reporting regulations with international standards for submitting safety information electronically. FDA anticipates the final rule will enhance industry’s global pharmacovigilance practices by allowing manufacturers to use common data elements and transmission standards when submitting ICSRs to multiple regulators.
FDA published the proposed rule in August 2009. The Agency received comments from a total of seven commenters, who generally supported the proposal and agreed that requiring electronic submission of postmarketing safety reports would enhance public health and safety.
The final rule issued with a draft guidance for industry. The rule becomes effective June 10, 2015.
This statement is also available on the FDA website at:  http://www.fda.gov/Drugs/DrugSafety/ucm4005a26.htm

The Small Business and Industry Assistance program in the Center for Drug Evaluation and Research (CDER SBIA) provides guidance and information to regulated domestic and international small pharmaceutical business and industry through its website, email notifications, and workshops. This notification system provides current information from CDER/FDA via e-mail on a biweekly basis that is relevant to small pharmaceutical business, which includes Federal Register notices, guidances, workshop announcements, etc. This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, please contact us Monday through Friday 8:00AM - 4:30PM.
Please take our CDER Small Business survey: https://www.surveymonkey.com/s/CDERSBIA_Evaluation

No hay comentarios: